Anne Chiang, MD, PhD
Immunotherapy has the potential to change the treatment paradigm of small cell lung cancer (SCLC), said Anne Chiang, MD, PhD. Moreover, recent results with immunotherapy agents in the second-line setting have already influenced guidelines.
, Chiang, a professor and thoracic oncologist at Yale Cancer Center, discussed recent developments with immunotherapy and the overall outlook for the treatment landscape of SCLC.
OncLive: Can you provide some insight on the current treatment landscape of SCLC?
: The landscape has changed, and that is something that is very new for SCLC because it hasn't changed that much in the past 30 years. Right now, the standard of care is giving a platinum doublet upfront for extensive-stage disease, and cisplatin and etoposide for limited-stage disease concurrent with radiation.
... to read the full story